← Eichor
Study identifier: NCT06414733 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

HER-2 B Cell Peptide Vaccine

Condition: Metastatic Breast Cancer · Metastatic Gastrointestinal Carcinoma · HER2-positive Breast Cancer  ·  Sponsor: Pravin T.P Kaumaya

PhasePhase 1
Planned participants42
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

This description comes directly from the study's public registry record.

Talk to the study team

Xin Bryan, RN  ·  317-274-5495  ·  zhongx@iu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Indiana University Melvin & Bren Simon Comprehensive Cancer CenterIndianpolis, Indiana, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06414733